Description
APOE affects multiple pathological processes including glial responses and blood-brain barrier function, all potentially contributing to cognitive decline. The relative importance and interactions between these mechanisms remain unclear, limiting therapeutic prioritization.
Gap type: unexplained_observation Source paper: APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. (2021, Lancet Neurol, PMID:33340485)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:48.727859+00:00”, “resolution_summary”: “Resolved by hypothesis h-0bcda2e0: CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-0bcda2e0”, “title”: “CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds”, “score”: 0.378, “reason”: “27 token overlaps; entity overlap: apoe, apoe-”, “analysis_id”: “SDA-2026-04-15-gap-debate-20260410-112607-0a3749ea”, “target_gene”: “APOE, CLU”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.811, “confidence_score”: 0.78, “status”: “promoted”, “pubmed_evidence_ids”: [“23296339”, “31564456”, “36348357”, “41422555”, “41606232”]}, {“id”: “h-3be15ed2”, “title”: “Astrocyte APOE4-Specific Lipid Metabolism Correction”, “score”: 0.358, “reason”: “22 token overlaps; entity overlap: apoe, apoe-”, “analysis_id”: “SDA-2026-04-03-gap-seaad-v4-20260402065846”, “target_gene”: “APOE”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.651, “confidence_score”: 0.5, “status”: “proposed”, “pubmed_evidence_ids”: [“33340485”, “35779013”, “36993867”]}, {“id”: “h-42f50a4a”, “title”: “Prime Editing Precision Correction of APOE4 to APOE3 in Microglia”, “score”: 0.356, “reason”: “21 token overlaps; entity overlap: apoe, apoe-”, “analysis_id”: “SDA-2026-04-03-gap-crispr-neurodegeneration-20260402”, “target_gene”: “APOE”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.826767, “confidence_score”: 0.7, “status”: “promoted”, “pubmed_evidence_ids”: [“39642875”, “40639927”, “41276911”, “41288387”, “41338186”]}, {“id”: “h-c9c79e3e”, “title”: “APOE4-Selective Lipid Nanoemulsion Therapy”, “score”: 0.352, “reason”: “24 token overlaps; entity overlap: apoe, apoe-”, “analysis_id”: “sda-2026-04-01-gap-auto-fd6b1635d9”, “target_gene”: “APOE”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.7416050000000001, “confidence_score”: 0.6, “status”: “proposed”, “pubmed_evidence_ids”: [“30078714”, “31515478”, “33712478”, “40145985”, “40562635”]}, {“id”: “SDA-2026-04-16-hyp-96ec73b3”, “title”: “APOE4-Driven Astrocyte Senescence as Primary Target”, “score”: 0.351, “reason”: “21 token overlaps; entity overlap: apoe, apoe-”, “analysis_id”: “SDA-2026-04-04-gap-senescent-clearance-neuro”, “target_gene”: “APOE,CDKN1A,BCL2L1”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: null, “composite_score”: 0.629, “confidence_score”: 0.46, “status”: “proposed”, “pubmed_evidence_ids”: [“32581763”, “35779313”, “37749326”, “37777962”, “39901180”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0_task_9aae8fc5”, “title”: “The abstract mentions that pathological seeds have different characteristics and conformations, but the underlying molecular mechanisms that generate this diversity remain unclear. Understanding these mechanisms is critical for developing targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: Protein transmission in neurodegenerative disease. (2020, Nat Rev Neurol, PMID:32203399)”, “score”: 0.405, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.403, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “title”: “This study shows APOE4 carriers have enhanced beneficial innate immune responses, directly contradicting the established view of APOE4 as purely detrimental in neurodegeneration. This paradox challenges fundamental assumptions about APOE4’s role in AD pathogenesis.\n\nGap type: contradiction\nSource paper: APOE genotype-specific differences in the innate immune response (2021, JAMA Neurology, PMID:33432245)”, “score”: 0.402, “reason”: “6 token overlaps; entity overlap: apoe, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “quality_score”: 0.6, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046_task_9aae8fc5”, “title”: “While the study establishes TDP-43 triggers mtDNA release via mPTP to activate cGAS/STING, it’s unclear why this pathway preferentially affects motor neurons in ALS when TDP-43 pathology occurs in multiple cell types. Understanding this selectivity is crucial for targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.353, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-165345-41805e1b_20260414-004616”, “title”: “The abstract shows microglia ameliorate OxPC toxicity to neurons and oligodendrocytes, but the specific neutralization mechanisms are not explained. Understanding these pathways could reveal therapeutic targets for MS neurodegeneration.\n\nGap type: unexplained_observation\nSource paper: Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. (None, None, PMID:33603230)”, “score”: 0.348, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-165345-41805e1b”, “quality_score”: 0.92, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}